Sentara Norfolk General Hospital
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sentara Norfolk General Hospital sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Sentara Norfolk General Hospital: 6 sponsored US clinical trials, 1 recruiting.
Sentara Norfolk General Hospital sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transplant;Failure,Kidney, with 1 trials.
Upper-quartile sponsor footprint
Sentara Norfolk General Hospital sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
NCT03886077
Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT03147430
Accelerated Partial Breast Irradiation Study
NCT03437395
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
NCT03760263
A Study to Evaluate Strategies for Teaching Effective Use of Diagnostic Tests
NCT04130607
Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)
NCT03148015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Therapeutic Areas
Where Sentara Norfolk General Hospital enrollment is open (later-stage tilt)
1 recruiting of 6 indexed (17% open); 3 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Transplant;Failure,Kidney (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sentara Norfolk General Hospital: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Sentara Norfolk General Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Sentara Norfolk General Hospital page
6 registered trials is a research-attention snapshot, not an endorsement of Sentara Norfolk General Hospital or any single study.
- 1 of Sentara Norfolk General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Transplant;Failure,Kidney is the condition Sentara Norfolk General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transplant;Failure,Kidney trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sentara Norfolk General Hospital pipeline card: 6 registered trials from official public datasets.Report a data error.